These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2045524)

  • 1. Therapeutic ratings and end-of-phase II conferences: initiatives to accelerate the availability of important new drugs.
    Kaitin KI; Phelan NR; Raiford D; Morris B
    J Clin Pharmacol; 1991 Jan; 31(1):17-24. PubMed ID: 2045524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The new drug approvals of 1987, 1988, and 1989: trends in drug development.
    Kaitin KI; DiCerbo PA; Lasagna L
    J Clin Pharmacol; 1991 Feb; 31(2):116-22. PubMed ID: 2010558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA advisory committees and the new drug approval process.
    Kaitin KI; Melville A; Morris B
    J Clin Pharmacol; 1989 Oct; 29(10):886-90. PubMed ID: 2592579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new drug approvals of 1990, 1991, and 1992: trends in drug development.
    Kaitin KI; Manocchia M; Seibring M; Lasagna L
    J Clin Pharmacol; 1994 Feb; 34(2):120-7. PubMed ID: 8163711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in drug development: the 1985-86 new drug approvals.
    Kaitin KI; Richard BW; Lasagna L
    J Clin Pharmacol; 1987 Aug; 27(8):542-8. PubMed ID: 3655005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA drug classification system.
    Sanborn MD; Godwin HN; Pessetto JD
    Am J Hosp Pharm; 1991 Dec; 48(12):2659-62. PubMed ID: 1814217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The new drug approvals of 1993, 1994, and 1995: trends in drug development.
    Kaitin KI; Manocchia M
    Am J Ther; 1997 Jan; 4(1):46-54. PubMed ID: 10423591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New indications for already-approved drugs: an analysis of regulatory review times.
    DiMasi JA; Kaitin KI; Fernandez-Carol C; Lasagna L
    J Clin Pharmacol; 1991 Mar; 31(3):205-15. PubMed ID: 2019661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A New Look At United States Drug Development and Approval Times.
    DiMasi JA
    Am J Ther; 1996 Sep; 3(9):647-657. PubMed ID: 11862306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigational drug tracking: phases I-III and NDA submissions--Part II.
    Grant KL
    Hosp Pharm; 1994 Oct; 29(10):900, 902-4, 906-11 passim. PubMed ID: 10137850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drug development by United States pharmaceutical firms with analyses of trends in the acquisition and origin of drug candidates, 1963-1979.
    Wardell WM; May MS; Trimble AG
    Clin Pharmacol Ther; 1982 Oct; 32(4):407-17. PubMed ID: 7116754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drug development during and after a period of regulatory change: clinical research activity of major United States pharmaceutical firms, 1958 to 1979.
    May MS; Wardell WM; Lasagna L
    Clin Pharmacol Ther; 1983 Jun; 33(6):691-700. PubMed ID: 6851401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The investigative process for new drugs.
    Nicklas RA
    Ann Allergy; 1989 Dec; 63(6 Pt 2):598-600. PubMed ID: 2688499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An appraisal of drug development timelines in the Era of precision oncology.
    Jardim DL; Schwaederle M; Hong DS; Kurzrock R
    Oncotarget; 2016 Aug; 7(33):53037-53046. PubMed ID: 27419632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of US Food and Drug Administration review intervals for drugs approved during the period 1997-2002.
    Kros JF; Qian J
    Am J Ther; 2004; 11(5):337-43. PubMed ID: 15356429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New indications for already-approved drugs: time trends for the new drug application review phase.
    Spivey RN; Lasagna L; Trimble AG
    Clin Pharmacol Ther; 1987 Apr; 41(4):368-70. PubMed ID: 3829575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigational drug tracking: Phases I-III and NDA submissions--Part I.
    Grant KL
    Hosp Pharm; 1994 Sep; 29(9):830-6, 839-44, 847-52 passim. PubMed ID: 10137064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.